Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop (Q38059720)

28 August 2017

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop (English)

1 reference

28 August 2017

0 references

6

1 reference

28 August 2017

7

1 reference

28 August 2017

19

Xavier Leleu

0 references

Efstathios Kastritis

16

object named as

Efstathios Kastritis

1 reference

28 August 2017

Andy C Rawstron

4

0 references

Enrique M Ocio

object named as

Enrique M Ocio

8

0 references

Robert A Kyle

2

object named as

Robert A Kyle

1 reference

28 August 2017

11

Kenneth C Anderson

1 reference

28 August 2017

20

Morie A Gertz

1 reference

28 August 2017

13

Nikhil C Munshi

1 reference

28 August 2017

18

Irene M Ghobrial

1 reference

28 August 2017

24

Steven P Treon

1 reference

28 August 2017

21

Stephen M Ansell

1 reference

28 August 2017

Roger G Owen

1

1 reference

28 August 2017

Marvin J Stone

3

1 reference

28 August 2017

Veronique Leblond

5

1 reference

28 August 2017

Enrica Morra

9

1 reference

28 August 2017

Pierre Morel

10

1 reference

28 August 2017

Christopher J Patterson

12

1 reference

28 August 2017

Alessandra Tedeschi

14

1 reference

28 August 2017

Douglas E Joshua

15

1 reference

28 August 2017

Evangelos Terpos

17

1 reference

28 August 2017

William G Morice

22

1 reference

28 August 2017

Eva Kimby

23

1 reference

28 August 2017

VIth International Workshop on Waldenström macroglobulinaemia

25

1 reference

28 August 2017

language of work or name

English

0 references

publication date

15 November 2012

1 reference

British Journal of Haematology

28 August 2017

1 reference

28 August 2017

160

1 reference

28 August 2017

2

1 reference

28 August 2017

171-176

1 reference

The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia

28 August 2017

1 reference

Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial.

21 January 2018

1 reference

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

21 January 2018

1 reference

Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom's macroglobulinemia.

21 January 2018

1 reference

Long-term biological variation of serum protein electrophoresis M-spike, urine M-spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies

21 January 2018

1 reference

Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia

21 January 2018

1 reference

Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study

21 January 2018

1 reference

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

21 January 2018

1 reference

Quantitation of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry

21 January 2018

1 reference

Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors

21 January 2018

1 reference

Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

21 January 2018

1 reference

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

21 January 2018

1 reference

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

21 January 2018

1 reference

Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation

21 January 2018

1 reference

Overestimation of monoclonal immunoglobulin by immunochemical methods

21 January 2018

1 reference

Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.

21 January 2018

1 reference

Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

21 January 2018

1 reference

Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia

21 January 2018

1 reference

Assessment of bone marrow response in Waldenström's macroglobulinemia

21 January 2018

1 reference

Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.12102

1 reference

28 August 2017

1 reference